Trastuzumab treatment need not delay breast reconstruction following mastectomy

(American College of Surgeons) Treatment with trastuzumab (Herceptin/Genentech) of breast cancers that express the HER-2 protein does not increase the risk for complications at the surgical site for women who undergo immediate breast reconstruction after mastectomy. The first study to assess the effect of trastuzumab on surgical wound complications indicates that breast reconstruction need not be delayed because of the type or length of this form of adjuvant therapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news